References

1. Regaud C. Sur Les Principles Radiophysiologiques De La Radiotherapie Des Cancers. Acta Radiol 1930;86:456-461.

2. Coutard H. Roentgen therapy of epitheliomas of the tonsillar region, hypopharynx and larynx from 1920 to 1926. Am J Roentgenol 1992;8:313-319.

3. Coutard H. Present conception of treatment of the larynx. Radiology 1940;34:136-145.

4. Ward JF. Mechanisms of DNA repair and their potential modification for radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12:1027-1032.

5. Haber JE. Partners and pathways repairing a double-strand break. Trends Genet 2000;16:259-264.

6. Cohen-Jonathan E, Bernhard E, McKenna GW. How does radiation kill? Curr Opin Chem Biol 1999;3:77-83.

7. Steel GG (ed). Clonogenic Cells and the Concept of Cell Survival in Basic Clinical Radiobiology. London: Arnold, 2002:52-54.

8. Cox JD. Proton beam radiation therapy in treatment of cancer. Clin Adv Hematol Oncol 2993;2:355-356.

9. Jagsi R, Delaney TF, Donelan K, Tarbell NJ. Real time rationing of scarce resources: the Northeast Proton Therapy Center experience. J Clin Oncol 2004;22:2246-2250.

10. Cline SD, Hanawalt PC. Who's on first in the cellular response to DNA damage? Nat Rev 2003;4:361-372.

11. Lindahl T, Wood RD. Quality control by DNA repair. Science 1000;286:1897-1905.

12. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair 2003;2:955-969.

13. Radivoyevitch T, Taverna P, Schupp JE, Kinsella TJ. The linear-quadratic log-survival radiation dose model: confidence ellipses, drug-drug interactions, and brachytherapeutic gains. Med Hypotheses Res 2004;1:23-28.

14. Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003;22:5792-5812.

15. Leskov KS, Criswell T, Antonio S, Yang C-R, Kinsella TJ, Boothman DA. When x-ray inducible proteins meet DNA double strand break repair. Semin Radiat Oncol 2001;11: 352-372.

16. Lee SE, Mitchell RA, Cheng A, et al. Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways as a function of the cell cycle. Mol Cell Biol 1997; 17:1425-1433.

17. Thompson LH. Evidence that mammalian cells possess homologous recombinational repair pathways. Mutat Res 1996;363:77-88.

18. Vandyck E, Stasiak AZ, Stasiak A, et al. Binding of double-strand breaks in DNA by human Rad 52 protein. Nature (Lond) 1999; 398:728-731.

19. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59: 928-942.

20. Sinclar W, Morton R. X-ray and ultraviolet sensitivity of synchronized Chinese hamster cells in culture. Nature (Lond) 1965;199:1158-1160.

21. Malumbres M, Baracid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-231.

22. Nagasawa H, Li CY, Maki CG, et al. Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res 1995;55:1842-1846.

23. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998; 12:2973-2983.

24. Sherr CJ. The Pezcoller Lecture: Cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.

25. Xu B, Kim SY, Lim DS, et al. Two molecularly distinct G(2)/M checkpoints are induced by ionizing radiation. Mol Cell Biol 2002;22:1049-1059.

26. Yamane K, Chen J, Kinsella TJ. Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2/M cell cycle checkpoint. Cancer Res 2003;63:3049-3053.

27. Yan T, Schupp JE, Hwang H-S, et al. Loss of DNA mismatch repair imparts defective cdc2 signaling and G2 arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290-8297.

28. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.

29. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;117:2941-2953.

30. Levin AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.

31. Thomlinson R, Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-544.

32. Brown JM. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism for reoxygenation. Br J Radiol 1979; 52:650-658.

33. Raleigh J, Dewhirst M, Thrall D. Measuring tumor hypoxia. Semin Radiat Oncol 1996;6:37-46.

34. Chaplin D, Olive P, Durand R. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987; 47:597-604.

35. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.

36. Kaanders J, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 2004;14:233-240.

37. Kaanders J, Wijffels KI, Marres , et al. Pomonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-7074.

38. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.

39. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.

40. Purdy JA. Defining our goals: volume and dose specification for 3-D conformal radiation therapy. In: Meyer JL, Purdy JA (eds). Frontiers of Radiation Therapy and Oncology. 3-D Conformal Radiotherapy: A New Era in the Irradiation of Cancer. Basel: Karger, 1996:24-30.

41. Prescribing, Recording, and Reporting Photon Beam Therapy. International Commission on Radiation Units and Measurements (ICRU) Report 50, Bethesda, MD: ICRU Publications; 1993.

42. Prescribing, Recording, and Reporting Photon Beam Therapy. International Commission on Radiation Units and Measurements (ICRU) Report 62 (Supplement to ICRU Report 50), Bethesda, MD: ICRU Publications; 1999.

43. Purdy JA. Dose-volume specification: new challenges with intensity-modulated radiation therapy. Semin Radiat Oncol 2002;12:199-209.

44. Low DA. Quality assurance of intensity-modulated radiotherapy. Semin Radiat Oncol 2002;12:219-228.

45. Falco T, Shenouda G, Kaufman C, et al. Ultrasound imaging for external-beam prostate treatment setup and dosimetric verification. Med Dosim 2000;27:271-273.

46. Zelefsky MJ, Fuks Z, Leibel SA. Intensity-modulated radiation therapy for prostate cancer. Sem Radiat Oncol 2002;12:229-237.

47. Eisbruch A, Foote RL, O'Sullivan B, Beitler J, Vikram B. Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2002;12:238-249s.

48. Ling CC, Mitchell JB. Functional imaging and its application to radiation oncology. Semin Radiat Oncol 2001;11:1-92.

49. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol 2000;10:73-93.

50. McDougall IR. Systemic radiation therapy with unsealed radionuclides. Semin Radiat Oncol 2000;10:94-102.

51. Houshmand P, Zlotnik A. Targetng tumor cells. Curr Opin Cell Biol 2003;15:640-644.

52. Hu KS, Enker WE, Harrison LB. High-dose rate intraoperative irradiation: current status and future directions. Semin Radiat Oncol 2002;12:62-80.

53. Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanaugh W. Brachytherapy for carcinoma of the prostate: techniques, patient selection and clinical outcomes. Semin Radiat Oncol 2002; 12:81-94.

54. Beaulieu L, Archambault L, Aubin S, et al. The robustness of dose distributions to displacement and migration of I-125 permanent seed implants over a wide range of seed number, activity, and designs. Int J Radiat Oncol Biol Phys 2004;58: 1298-1308.

55. Nguyen HP, Kaluza GL, Zymek PT, et al. Intracoronary brachytherapy. Catheter Cardiovasc Interv 2002;56:281-288.

56. Wang R, Li XA. Dosimetric comparison of two Sr-90/Y-90 sources for intravascular brachytherapy: an EGSnrc Monte Carlo calculation. Phys Med Biol 2002;47:4259-4269.

57. Streeter OE, Vicini FA, Keisch M, et al. MammoSite radiation therapy system. Breast 2003;12:491-496.

58. Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003;55:289-293.

59. Merrick HW, Dobelbower RR. Intraoperative radiation therapy in surgical oncology. Surg Oncol Clin N Am 2003;12:883-899.

60. Biggs PJ, Noyes RD, Willett CG. Clinical physics, applicator choice, technique, and equipment for electron intraoperative radiation therapy. Surg Oncol Clin N Am 2003;12:899-924.

61. Sindelar WF, Kinsella TJ. Normal tissue tolerance to intraoperative radiotherapy. Surg Oncol Clin N Am 2003;12:925-942.

62. Merrick HW, Thomas CR (eds). Intraoperative radiotherapy. Surg Oncol Clin N Am 2003;12:955-1078.

63. Sneed PK, Sun JN, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone versus radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002;53:519-526.

64. Lorenzoni J, Deuriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004;60:218-224.

65. McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001;11:270-280.

66. Lawrence TS, Blackstock G, McGinn CJ. The mechanisms of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003;13:13-21.

67. Vallerga AK, Zarling D, Kinsella TJ. New radiosensitizing regimens, drugs, prodrugs and candidates: Capecitabine, Gem-citabine, Fludarabine, IPdR, Avastin, Veglin, Gleevac, Radvac, Erbitux or Iressa. Clin Adv Hematol Oncol 2004;2: 793-805.

68. Hwang H-S, Davis TW, Houghton JA, Kinsella TJ. Radiosensi-tivity of thymidylate synthase deficient human colon cancer cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitiza-tion. Cancer Res 2000;60:92-100.

69. Kuo M-L, Kinsella TJ. Expression of ribonucleotide reductase following ionizing radiation in human cervical carcinoma cells. Cancer Res 1998;58:2245-2252.

70. Kuo M-L, Hwang H-S, Sosnay PR, Kunugi KA, Kinsella TJ. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J (Boston) 2003;9:277-285.

71. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38:240-257.

72. Stratford IJ, Williams KJ, Cowen RL, Jaffar M. Combining biore-ductive drugs and radiation for the treatment of solid tumors. Semin Radiat Oncol 2003;13:42-52.

73. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosen-sitized in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study Protocol 5-85. Radio-ther Oncol 1998;46:135-146.

74. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 2003; 13:22-30.

75. Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 2003;13:53-61.

76. Bonner JA, Trigo J, Humblet Y, et al. Phase 3 trial of radiation therapy plus cetuximab versus radiation therapy alone in locally advanced squamous cell carcinomas of the head and neck. Proc ASCO 2004;23:487.

77. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001;11:290-299.

78. McKenna WG, Muschell RJ, Gupta AK, Hahn SM, Bernhard EJ. Farinesyltransferase inhibitors as radiation sensitizers. Semin Radiat Oncol 2002;12(suppl 2):27-32.

79. Jung M, Dritschilp A. NF-kß signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 2001; 11:346-351.

80. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis (Oxf) 2001;22:1921-1937.

81. Yan T, Schupp JE, Hwang H-S, et al. Loss of DNA mismatch repair imparts defective cdc2 signaling and G2 arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290-8297.

82. Berry SE, Kinsella TJ. Targeting DNA mismatch repair for radiosensitization. Semin Radiat Oncol 2001; 11:300315.

83. Seo Y, Yan T, Schupp JE, Kinsella TJ. Differential radiosensitization in DNA mismatch repair proficient and deficient human colon cancer xenografts with 5-iodo-pyrimidinone-2'-deoxyri-bose. Clin Cancer Res 2004;10:7520-7528.

84. Russell JS, Brady K, Burgan WE, et al. Gleevac-mediated inhibition of RAD51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003;63:7377-7383.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment